Bond W S
J Clin Psychopharmacol. 1986 Apr;6(2):81-7.
Clonidine's actions and efficacy in mental disorders are reviewed and examined. Its efficacy in suppressing acute opiate withdrawal symptoms and its role in preparing the opiate-dependent patient for transition from opiate agonist to naltrexone therapy are well documented. Studies also indicate clonidine's value in alcohol and tobacco withdrawal syndromes. Of special interest is evidence which suggests that clonidine can reduce the duration and cost of the withdrawal process. Also discussed is clonidine's utility for mania, anxiety and panic disorders, schizophrenia, and the symptoms of tardive dyskinesia. Although further documentation of its efficacy for these disorders is required, clonidine's efficacy as an antimanic agent and treatment for tardive dyskinesia is particularly exciting and worthy of further study.
本文回顾并探讨了可乐定在精神障碍中的作用及疗效。其在抑制急性阿片戒断症状方面的疗效以及在帮助阿片依赖患者从阿片激动剂过渡到纳曲酮治疗过程中的作用已有充分记录。研究还表明可乐定在酒精和烟草戒断综合征中的价值。特别值得关注的是有证据表明可乐定可缩短戒断过程的持续时间并降低成本。文中还讨论了可乐定在躁狂症、焦虑症和恐慌症、精神分裂症以及迟发性运动障碍症状方面的效用。尽管需要进一步证明其对这些疾病的疗效,但可乐定作为抗躁狂药物和治疗迟发性运动障碍的疗效尤其令人兴奋,值得进一步研究。